Aclaris Therapeutics, Inc. revenue
Aclaris Therapeutics, Inc.'s revenue was $7.8m in fiscal 2025, down 58.2% on the year before. Since fiscal 2017 ($1.7m) it has grown at a compound 21.2% a year. Over the last twelve months it was $8.2m.
Revenue history
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 6 | 4 | 6 | 7 | 30 | 31 | 19 | 8 | 8 |
| Growth on the year before | — | +265.5% | −31.3% | +53.3% | +4.3% | +340.1% | +5.0% | −40.1% | −58.2% | — |
| Gross profit | 0 | 3 | 0 | 1 | 2 | 26 | 28 | 16 | 6 | 7 |
| Gross margin | 28.3% | 52.7% | 4.1% | 20.8% | 30.3% | 86.5% | 89.0% | 85.1% | 73.3% | 79.5% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Licenses and services | $6M | 76.1% | ▼ 63.2% |
| Laboratory Research Revenue | $1.9M | 23.9% | ▼ 26.3% |
From Aclaris Therapeutics, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Aclaris Therapeutics, Inc. | $8.2m | -51.0% | -35.9% |
| Coya Therapeutics, Inc. | $8.0m | 1793.8% | — |
| Apollomics Inc. | $8.5m | — | — |
| Adagene Inc. | $7.7m | 7332.8% | — |
| Roivant Sciences Ltd. | $7.5m | -67.6% | -46.4% |
| Evaxion A/s | $7.5m | 125.1% | — |
Compare with peers
- Coya Therapeutics, Inc. revenue
- Apollomics Inc. revenue
- Adagene Inc. revenue
- Roivant Sciences Ltd. revenue
- Evaxion A/s revenue
Head to head: ACRS vs COYAACRS vs APLMACRS vs ADAG
More: Biotechnology stocks compared, Health Care sector, rankings of US companies